Proteinases and plaque rupture: Unblocking the road to translation

Current Opinion in Lipidology

Volumn 25, Issue 5, 2014, Pages 358-366

  Newby, Andrew C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Atherosclerosis; Cathepsins; Metalloproteinases; Plaque rupture; Serine proteinases

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE WITH THROMBOSPONDIN; ADAM10 ENDOPEPTIDASE; ADAM33 METALLOPROTEINASE; ADAMTS7 PROTEIN; CATHEPSIN; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN S INHIBITOR; CHYMASE; COLLAGENASE 3; DOXYCYCLINE; LEUKOCYTE ELASTASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 28; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PLASMIN; PROTEINASE; SERINE PROTEINASE; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; ADAM33 PROTEIN, HUMAN; MEMBRANE PROTEIN; SECRETASE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DRUG TARGETING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE THERAPY; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PLAQUE RUPTURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR REMODELING; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; MACROPHAGE; METABOLISM; MOLECULARLY TARGETED THERAPY; MYOCARDIAL INFARCTION; PATHOLOGY;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ATHEROSCLEROSIS; CATHEPSIN K; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC;

EID: 84921433970     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000111     Document Type: Review

References (92)

1. Wight TN. The extracellular matrix and atherosclerosis. Curr Opin Lipidol 1995; 6: 326-334.
2. Thyberg J, Blomgren K, Roy J, et al. Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 1997; 45: 837-846.
3. Aguilera CM, George SJ, Johnson JL, Newby AC. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 2003; 58: 679-688.
4. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007; 100: 607-621.
5. Bond M, Sala-Newby GB, Newby AC. Focal adhesion kinase (FAK)-dependent regulation of S-phase kinase-associated protein-2 (Skp-2) stability. A novel mechanism regulating smooth muscle cell proliferation. J Biol Chem 2004; 279: 37304-37310.
6. Tsaousi A, Mill C, George SJ. The Wnt pathways in vascular disease: Lessons from vascular development. Curr Opin Lipidol 2011; 22: 350-357; 310.1097/MOL.1090b1013e32834aa32701.
7. Pfenniger A, Chanson M, Kwak BR. Connexins in atherosclerosis. Biochim Biophys Acta 2013; 1828: 157-166.
8. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
9. Libby P. Collagenases and cracks in the plaque. J Clin Invest 2013; 123: 3201-3203.
10. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-C18.
11. Rodriguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010; 1803: 39-54.
12. Matoba T, Sato K, Egashira K. Mouse models of plaque rupture. Curr Opin Lipidol 2013; 24: 419-425; 410.1097/MOL.1090b1013e 3283646e3283644d.
13. Johnson JL, Carson K,Williams HM, et al. Plaque rupture after short periods of fat-feeding in the apolipoprotein E knockout mouse: Model characterisation, and effects of pravastatin treatment. Circulation 2005; 111: 1422-1430.
14. Falk E, Schwartz SM, Galis ZS, Rosenfeld ME. Putative murine models of plaque rupture. Arterioscler Thromb Vasc Biol 2007; 27: 969-972.
15. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
16. Sjoberg S, Shi GP. Cysteine protease cathepsins in atherosclerosis and abdominal aortic aneurysm. Clin Rev Bone Min Metab 2011; 9: 138-147.
17. Cheng XW, Huang Z, Kuzuya M, et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011; 58: 978-986.
18. Shi HT, Wang Y, Jia LX, et al. Cathepsin S contributes to macrophage migration via degradation of elastic fibre integrity to facilitate vein graft neointimal hyperplasia. Cardiovasc Res 2014; 101: 454-463.
19. Mahmood DF, Jguirim-Souissi I, Khadija el H, et al. Peroxisome proliferatoractivated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: Potential role in atherosclerosis. J Biol Chem 2011; 286: 28858-28866.
20. Wei DH, Jia XY, Liu YH, et al. Cathepsin L stimulates autophagy and inhibits apoptosis of ox-LDL-induced endothelial cells: Potential role in atherosclerosis. Int J Mol Med 2013; 31: 400-406.
21. Rafatian N, Karunakaran D, Rayner KJ, et al. Cathepsin G deficiency decreases complexity of atherosclerotic lesions in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2013; 305: H1141-1148.
22. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
23. Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PloS One 2010; 5: E11765.
24. Samokhin AO, Lythgo PA, Gauthier JY, et al. Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice. J Cardiovasc Pharmacol 2010; 56: 98-105.
25. Novinec M, Lenarcic B. Cathepsin K. a unique collagenolytic cysteine peptidase. Biol Chem 2013; 394: 1163-1179.
26. Lutgens E, Lutgens SP, Faber BC, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006; 113: 98-107.
27. Shon SM, Choi Y, Kim JY, et al. Photodynamic therapy using a proteasemediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol 2013; 33: 1360-1365.
28. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis 2012; 222: 8-14.
29. Spinetti G, Fortunato O, Cordella D, et al. Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res 2011; 108: 284-293.
30. Henriksen PA, Sallenave JM. Human neutrophil elastase: Mediator and therapeutic target in atherosclerosis. Int J BiochemCell Biol2008; 40: 1095-1100.
31. Swedenborg J, Mayranpaa MI, Kovanen PT. Mast cells: Important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011; 31: 734-740.
32. Bot I, Biessen EA. Mast cells in atherosclerosis. Thromb Haemost 2011; 106: 820-826.
33. Wagsater D, Johansson D, Fontaine V, et al. Serine protease inhibitor A3 in atherosclerosis and aneurysm disease. Int J Mol Med 2012; 30: 288-294.
34. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Hamost 2001; 86: 324-333.
35. Farris SD, Hu JH, Krishnan R, et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: Role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 2011; 286: 22665-22677.
36. Das R, Ganapathy S, Mahabeleshwar GH, et al.Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation 2013; 127: 1209-1218.
37. Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques: Production by macrophages. Circulation 2003; 107: 2829-2836.
38. Iwata K, Doi A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): A systematic review and meta-analysis. Intern Med 2010; 49: 2423-2432.
39. Lucas SD, Costa E, Guedes RC, Moreira R. Targeting COPD: Advances on low-molecular-weight inhibitors of human neutrophil elastase. Med Res Rev 2013; 33 (Suppl 1): E73-E101.
40. Feng L, Liu X, Zhu W, et al. Inhibition of human neutrophil elastase by pentacyclic triterpenes. PloS One 2013; 8: E82794.
41. Madsen JL, Andersen TL, Santamaria S, et al. Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase. J Med Chem 2012; 55: 7900-7908.
42. Korkmaz B, Jenne DE, Gauthier F. Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases. Int Immunopharmacol 2013; 17: 1198-1205.
43. Guo T, Wang J, Yang J, et al. Lentivirus-mediated RNA interference of chymase increases the plaque stability in atherosclerosis in vivo. Exp Mol Pathol 2013; 95: 51-56.
44. Plihtari R, Hurt-Camejo E, Oorni K, Kovanen PT. Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase. J Lipid Res 2010; 51: 1801-1809.
45. van der Vorst EP, Keijbeck AA, de Winther MP, Donners MM. A disintegrin and metalloproteases: Molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012; 224: 302-308.
46. Thorp E, Vaisar T, Subramanian M, et al. Shedding of the MER tyrosine kinase receptor is mediated by ADAM17 through a pathway involving reactive oxygen species, protein kinase {delta}, and P38 map kinase. J Biol Chem 2011; 286: 33335-33344.
47. Raitoharju E, Seppala I, Levula M, et al. Common variation in the ADAM8 gene affects serum sADAM8 concentrations and the risk of myocardial infarction in two independent cohorts. Atherosclerosis 2011; 218: 127-133.
48. Figarska SM, Vonk JM, van Diemen CC, et al. ADAM33 gene polymorphisms and mortality. A prospective cohort study. PloS One 2013; 8: E67768.
49. Bultmann A, Li Z, Wagner S, et al. Loss of protease activity of ADAM15 abolishes protective effects on plaque progression in atherosclerosis. Int J Cardiol 2011; 152: 382-385.
50. Smiljanic K, Dobutovic B, Obradovic M, et al. Involvement of the ADAM 12 in thrombin-induced rat's VSMCs proliferation. Curr Med Chem 2011; 18: 3382-3386.
51. Salter RC, Ashlin TG, Kwan AP, Ramji DP. ADAMTS proteases: Key roles in atherosclerosis? J Mol Med 2010; 88: 1203-1211.
52. Salter RC, Arnaoutakis K, Michael DR, et al. The expression of a disintegrin and metalloproteinase with thrombospondin motifs 4 in human macrophages is inhibited by the antiatherogenic cytokine transforming growth factor-beta and requires Smads, p38 mitogen-activated protein kinase and c-Jun. Int J Biochem Cell Biol 2011; 43: 805-811.
53. Wang L, Zheng J, Bai X, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res 2009; 104: 688-698.
54. Wang L, Zheng J, Du Y, et al. Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with alpha(7)beta(1) integrin. Circ Res 2010; 106: 514-525.
55. Reilly MP, Li M, He J, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: Two genome-wide association studies. Lancet 2011; 377: 383-392.
56. Pu X, Xiao Q, Kiechl S, et al. ADAMTS7 cleavage and vascular smooth muscle cell migration is affected by a coronary-artery-disease-associated variant. Am J Human Genet 2013; 92: 366-374.
57. van Setten J, Isgum I, Smolonska J, et al. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis 2013; 228: 400-405.
58. Du Y, Wang Y, Wang L, et al. Cartilage oligomeric matrix protein inhibits vascular smooth muscle calcification by interacting with bone morphogenetic protein-2. Circ Res 2011; 108: 917-928.
59. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vasc Pharmacol 2012; 56: 232-244.
60. Peeters W, Moll FL, Vink A, et al. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J 2011; 32: 2314-2325.
61. Scholtes VPW, Johnson JL, Jenkins N, et al. Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy. J Am Heart Assoc 2012; 1: E001040.
62. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: A study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37: 235-239.
63. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006; 69: 677-687.
64. Jin Y, Roycik MD, Bosco DB, et al. Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core. Journal of Medicinal Chemistry 2013; 56: 4357-4373.
65. Johnson JL, Sala-Newby GB, Ismail Y, et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 1647-1653.
66. Lenglet S, Mach F, Montecucco F. Role of matrix metalloproteinase-8 in atherosclerosis. Mediators of inflammation 2013; 2013: 659282.
67. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 2009; 105: 921-929.
68. Xiao Q, Zhang F, Lin L, et al. Functional role of matrix metalloproteinase-8 in stem/progenitor cell migration and their recruitment into atherosclerotic lesions. Circ Res 2013; 112: 35-47.
69. Xiao Q, Zhang F, Grassia G, et al. Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. Arterioscler Thromb Vasc Biol 2014; 34: 90-98.
70. Quillard T, Araujo HA, Franck G, et al. Matrix metalloproteinase-13 predominates over matrix metalloproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol 2014; 34: 1179-1186.
71. Quillard T, Tesmenitsky Y, Croce K, et al. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 2464-2472.
72. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-2509.
73. Huang WC, Sala-Newby GB, Susana A, et al. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-kappaB. PloS One 2012; 7: E42507.
74. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003; 126: 2738-2749.
75. Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase- 8 in patients with unstable angina. Atherosclerosis 2010; 209: 206-210.
76. Di Gregoli K, Jenkins NP, Salter RC, et al. MicroRNA-24 regulates macrophage behaviour and retards atherosclerosis. Arterioscler Thromb Vasc Biol 2014. [Epub ahead of print]
77. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102: 15575-15580.
78. Johnson JL, Devel L, Czarny B, et al. A Selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein e-knockout mice. Arterioscler Thromb Vasc Biol 2011; 31: 528-535.
79. Dahl R, Titlestad I, Lindqvist A, et al. Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial. Pulm Pharmacol Ther 2012; 25: 169-177.
80. Lenglet S, Thomas A, Chaurand P, et al. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. ThrombHaemost2012;107: 409-416.
81. Reel B, Sala-Newby GB, Huang W-C, Newby AC. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br J Pharmacol 2011; 163: 1679-1690.
82. Rodriguez JA, Orbe J, Martinez de Lizarrondo S, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci 2008; 13: 2916-2921.
83. de Lizarrondo SM, Roncal C, Calvayrac O, et al. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol 2012; 32: 1477-1487.
84. Jackson V, Olsson T, Kurtovic S, et al. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2012; 144: 450-466.
85. Pei D. Leukolysin/MMP25/MT6-MMP: A novel matrix metalloproteinase specifically expressed in the leukocyte lineage. Cell Res 1999; 9: 291-303.
86. Ma Y, Halade GV, Zhang J, et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res 2013; 112: 675-688.
87. de Vries MR, Niessen HW, Lowik CW, et al. Plaque rupture complications in murine atherosclerotic vein grafts can be prevented by TIMP-1 overexpression. PloS One 2012; 7: E47134.
88. Casagrande V, Menghini R, Menini S, et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in lowdensity lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2012; 32: 74-81.
89. Gill SE, Gharib SA, Bench EM, et al. Tissue inhibitor of metalloproteinases-3 moderates the proinflammatory status of macrophages. Am J Resp Cell Mol 2013; 49: 768-777.
90. Eefting D, de Vries MR, Grimbergen JM, et al. In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1. ATF), a cell-surface directed matrix metalloproteinase inhibitor. J Vasc Surg 2010; 51: 429-437.
91. George SJ, Wan S, Hu J, et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011; 124: S135-S142.
92. Monaco C, Gregan SM, Navin TJ, et al. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009; 120: 2462-2469.